Puttemans, J.; Dekempeneer, Y.; Eersels, J.L.; Hanssens, H.; Debie, P.; Keyaerts, M.; Windhorst, A.D.; van der Aa, F.; Lecocq, Q.; Breckpot, K.;
et al. Preclinical Targeted α- and β−-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies. Cancers 2020, 12, 1017.
https://doi.org/10.3390/cancers12041017
AMA Style
Puttemans J, Dekempeneer Y, Eersels JL, Hanssens H, Debie P, Keyaerts M, Windhorst AD, van der Aa F, Lecocq Q, Breckpot K,
et al. Preclinical Targeted α- and β−-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies. Cancers. 2020; 12(4):1017.
https://doi.org/10.3390/cancers12041017
Chicago/Turabian Style
Puttemans, Janik, Yana Dekempeneer, Jos L. Eersels, Heleen Hanssens, Pieterjan Debie, Marleen Keyaerts, Albert D. Windhorst, Frank van der Aa, Quentin Lecocq, Karine Breckpot,
and et al. 2020. "Preclinical Targeted α- and β−-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies" Cancers 12, no. 4: 1017.
https://doi.org/10.3390/cancers12041017
APA Style
Puttemans, J., Dekempeneer, Y., Eersels, J. L., Hanssens, H., Debie, P., Keyaerts, M., Windhorst, A. D., van der Aa, F., Lecocq, Q., Breckpot, K., Morgenstern, A., Bruchertseifer, F., Lahoutte, T., Devoogdt, N., & D’Huyvetter, M.
(2020). Preclinical Targeted α- and β−-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies. Cancers, 12(4), 1017.
https://doi.org/10.3390/cancers12041017
